Please assess the completion status of the following clinical trial:

Trial Title: Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have taken PPI (omeprazole or equivalent ≥ 20 mg/day, ≥ three times per week, for at least 2 months)~* Expected to continue at a similar dosage~* Stage 1 hypertension (with systolic blood pressure \<140 and diastolic \<90)~* controlled diabetes mellitus Type II with HbA1C less than 7%~Exclusion Criteria:~* end-stage renal failure on dialysis~* hypercalcemia~* hypophosphatemia (serum P \< 2.5 mg/dL)~* hypertension stage 2 or higher~* diabetes Type II with HbA1C ≥ 7%~* treatment with adrenocorticosteroids, diuretics, non-steroidal anti-inflammatory agents~* regular dose of magnesium supplements, bisphosphonate, teriparatide, denosumab or selective estrogen receptor modulators.~Inclusion/exclusion of other drugs or conditions will be considered on an individual basis.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- EffCaMgCit (Type: EXPERIMENTAL): 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate; designed to be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. Each sachet of EffCaMgCit will contain 400 units of vitamin D.
- Placebo (Type: PLACEBO_COMPARATOR): Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.

Based on this trial design, predict the completion outcome and termination type (if applicable).